Charles River Laboratories International, Inc. (CRL) News
Follow Charles River Laboratories International, Inc. (CRL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 48 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Charles River collaborates with Magellan Stem Cells
The companies are collaborating to advance stem cell and regenerative medicine development.
EQUITY | Oct 13, 2026, 12:08 PM UTC
M
Biotech Stocks Surge to 52-Week Highs on Strong Clinical Data
Several biotech stocks reached new 52-week highs on October 5, 2026, propelled by positive clinical research data and strong Phase 3 results. Vaxcyte Inc. (PCVX) saw a significant jump of 31%, while INFU and ILMN rose 7%
EQUITY | Oct 06, 2026, 07:52 AM UTC
L
Charles River Labs Is Maintained at Buy by Jefferies
Ratings actions from Benzinga: GMT) Charles River Labs Price Target Raised to $340.00/Share From $305.00 by JefferiesRatings actions from Benzinga
NEWS | Sep 28, 2026, 02:13 PM UTC
L
Charles River Labs Price Target Raised to $320.00/Share From $300.00 by Deutsche Bank
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 04:40 PM UTC
L
Charles River Labs Price Target Raised to $325.00/Share From $300.00 by TD Cowen
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 02:34 PM UTC
L
Charles River Labs Is Maintained at Outperform by Evercore ISI Group
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 02:32 PM UTC
L
TD Cowen maintains Buy rating on Charles River, $325 price target
TD Cowen maintained their Buy rating on Charles River's stock with a price target of $325.00.The price target implies an upside of 10.4% from the Sep 24 close of $294.44.Key takeaways from the analyst noteStrong Historic
EQUITY | Sep 25, 2026, 02:24 PM UTC
L
Charles River Labs Is Maintained at Outperform by RBC Capital
Ratings actions from Benzinga: GMT) Charles River Labs Price Target Raised to $322.00/Share From $282.00 by RBC CapitalRatings actions from Benzinga
NEWS | Sep 25, 2026, 01:55 PM UTC
L
RBC Capital maintains Outperform rating on Charles River, $322 price target
RBC Capital maintained their Outperform rating on Charles River's stock with a price target of $322.00.The price target implies an upside of 9.4% from the Sep 24 close of $294.44.Key takeaways from the analyst noteStrong
EARNINGS | Sep 25, 2026, 01:45 PM UTC
L
Charles River Labs Is Maintained at Overweight by Barclays
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 12:42 PM UTC
L
Charles River Labs Price Target Raised to $295.00/Share From $264.00 by Mizuho
Ratings actions from Benzinga: GMT) Charles River Labs Is Maintained at Neutral by MizuhoRatings actions from Benzinga
NEWS | Sep 25, 2026, 12:25 PM UTC
L
Charles River Labs Price Target Raised to $334.00/Share From $291.00 by Baird
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 11:36 AM UTC
H
S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today
The S&P 500 clawed back most of its morning decline at midday Thursday after sources told Reuters that U.S. and Iranian negotiators meeting in New York are discussing a phased deal that would have Tehran reopen the Strai
LIVE | Sep 24, 2026, 05:32 PM UTC
H
Why Charles River Laboratories (CRL) Stock Is Up Today
What Happened? Shares of lab services company Charles River Laboratories NYSE:CRLjumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlo
EARNINGS | Sep 24, 2026, 04:45 PM UTC
H
Charles River outlines Pathway to Purpose, reaffirms 2026 guidance and sets 2030 targets
Charles River announced a refreshed Pathway to Purpose strategy, reaffirmed 2026 guidance at the upper end of prior ranges, and set long-term financial targets through 2030.Key Highlights:Original SEC Filing: CHARLES RIV
REGULATION | Sep 24, 2026, 01:05 PM UTC
H
Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7%
Charles River Laboratories International, Inc. (NYSE: CRL ) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET. The Company is also introducing the following long-term financial targets t
LIVE | Sep 24, 2026, 12:08 PM UTC
L
Charles River Labs Targets 2027-2030 Adj EPS Growth in Low-Double-Digits
Charles River Labs Targets 2027-2030 Adj EPS Growth in Low-Double-Digits
EARNINGS | Sep 24, 2026, 12:07 PM UTC
L
Charles River Labs Sees FY26 Organic Rev Growth at Upper End of 0%-1% Range >CRL
Charles River Labs Sees FY26 Organic Rev Growth at Upper End of 0%-1% Range >CRL
NEWS | Sep 24, 2026, 12:07 PM UTC
L
Charles River Labs Sees FY26 Adj EPS at Upper End of $11.15-$11.45 Range >CRL
Charles River Labs Sees FY26 Adj EPS at Upper End of $11.15-$11.45 Range >CRL
EARNINGS | Sep 24, 2026, 12:06 PM UTC
L
Charles River Labs Targets 2027-2030 Organic Revenue Growth of 5%-7%>CRL
Charles River Labs Targets 2027-2030 Organic Revenue Growth of 5%-7%>CRL
NEWS | Sep 24, 2026, 12:05 PM UTC
L
Charles River Expects Bioanalysis Rev to Grow Organically at High-Single-Digit CAGR to About $450 M in 2030 >CRL
Charles River Expects Bioanalysis Rev to Grow Organically at High-Single-Digit CAGR to About $450 M in 2030 >CRL
NEWS | Sep 24, 2026, 12:03 PM UTC
L
Charles River Will Expand Use of AI-assisted Digital Tools to Improve Oper Efficiency, Reduce Drug Development Timelines >CRL
Charles River Will Expand Use of AI-assisted Digital Tools to Improve Oper Efficiency, Reduce Drug Development Timelines >CRL
NEWS | Sep 24, 2026, 12:03 PM UTC
L
Charles River Expects Over $300 M in Cumulative Savings From 2027 Through 2030 by Simplifying Processes and Increasing Automation >CRL
Charles River Expects Over $300 M in Cumulative Savings From 2027 Through 2030 by Simplifying Processes and Increasing Automation >CRL
NEWS | Sep 24, 2026, 12:02 PM UTC
H
Charles River Backs 2026 Guidance With Rev, Adj EPS Expected at Upper Ends of Prior Ranges >CRL
Charles River Backs 2026 Guidance With Rev, Adj EPS Expected at Upper Ends of Prior Ranges >CRL
EARNINGS | Sep 24, 2026, 12:02 PM UTC
H
Charles River Laboratories International, Inc. (CRL) Reaffirms 2026 Outlook, Adds 2030 Targets
Charles River reaffirmed its 2026 guidance, now expecting revenue and non-GAAP EPS at the upper ends of prior ranges, and introduced long-term financial targets through 2030.Material DetailsContext by AI AnalystThis is a
EARNINGS | Sep 24, 2026, 12:01 PM UTC
L
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.Birgit Girshick, Chief Executive Officer, along with members of the senior ma
NEWS | Sep 24, 2026, 12:00 PM UTC
L
CRL - Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
CRL - Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
NEWS | Sep 17, 2026, 12:03 PM UTC
L
CRL: Strong bookings, operational modernization, and supply chain investments drive margin growth
Leadership transition has been smooth, with a renewed focus on modernization and client-centric growth. Strong financial performance is supported by robust bookings and backlog recovery, while operational improvements an
NEWS | Sep 15, 2026, 03:54 PM UTC
L
CRL: Leadership transition and strategic execution are fueling growth, margin expansion, and operational resilience
New leadership is driving a strategy focused on modernization, operational efficiency, and client-centric growth, with strong recent financial performance and improved margins. Investments in supply chain and portfolio o
NEWS | Sep 15, 2026, 02:49 PM UTC
L
CRL - Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
CRL - Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
EQUITY | Sep 08, 2026, 12:06 PM UTC
L
Charles River implements automated Endosafe cartridge manufacturing suite
Charles River Laboratories International implemented its Endosafe Cartridge Technology Automated Manufacturing Suite to expand in-process inspection and digital traceability for bacterial endotoxin testing cartridge prod
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
Charles River Laboratories partners with Medigen on sequencing programs
Charles River Laboratories (CRL) and Medigen Vaccine Biologics Corp collaborate to advance new vaccine development programs through next generation sequencing.
MNA | Aug 20, 2026, 12:08 PM UTC
L
Charles River Laboratories, Medigen Vaccine Biologics Collaborate on Vaccine Programs
Charles River Laboratories and Medigen Vaccine Biologics Corp collaborate to advance new vaccine development programs through next-generation sequencing.
MNA | Aug 20, 2026, 12:01 PM UTC
H
Citrini Initiates Long Position
Citrini takes long position
EQUITY | Aug 10, 2026, 05:01 PM UTC
H
JPM Upgrades CRL To Overweight
JPM upgrades CRL to overweight
EQUITY | Aug 06, 2026, 11:28 AM UTC
H
Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today
Gold ripped 4% higher to $4,233.89 an ounce on Wednesday, its biggest one-day advance since February, as a soft private payrolls report and easing energy costs knocked down the odds of another Federal Reserve rate hike.
EARNINGS | Aug 05, 2026, 06:14 PM UTC
H
Charles River Says Biotech Demand Is Back — Bookings Hit Four-Year High
Charles River Laboratories International Inc. (NYSE: CRL ) stock traded higher Wednesday after the contract research organization raised its full-year 2026 financial guidance following second-quarter results that exceede
EARNINGS | Aug 05, 2026, 06:03 PM UTC
H
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Wednesday. Shares of Wynn Resorts Ltd (NASDAQ: WYNN ) rose sharply after the company reported better-than- expected quarterly financial resul
EARNINGS | Aug 05, 2026, 02:01 PM UTC
H
Shopify Beats Revenue Estimates
Shopify reports revenue beat
EARNINGS | Aug 05, 2026, 11:07 AM UTC
H
Charles River Raises FY2026 Adj EPS Guidance from $10.80-$11.30 to $11.15-$11.45 vs $11.12 Est; Raises FY2026 Sales Guidance from $3.794B-$3
Charles River (NYSE: CRL ) raises FY2026 Adj EPS guidance from $10.80-$11.30 to $11.15-$11.45 vs $11.12 analyst estimate. Raises FY2026 sales outlook from $3.794 billion-$3.854 billion to $3.879 billion-$3.920 billion vs
EARNINGS | Aug 05, 2026, 11:02 AM UTC
H
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE: SHW ) rose sharply after the company reported better-than-expected second-quarter financial resu
EARNINGS | Jul 28, 2026, 02:05 PM UTC
H
IQV shares +10% premarket after results and guidance as raises FY2026 adj EPS forecast to $12.80-$13.00 from prior forecast of $12.65-$12.95
IQV shares +10% premarket after results and guidance as raises FY2026 adj EPS forecast to $12.80-$13.00 from prior forecast of $12.65-$12.95as midpoint tops ests $12.90; posted Q2 EPS and rev beat $4.37B vs. est. $4.3B -
EARNINGS | Jul 28, 2026, 12:48 PM UTC
L
moves among today's downgrades PENG -11.4%, FNB -2.6%, CRL -2.5%, BIRK -2.2%, FDUS -2.1%, HUBS -1.7%, ATAI -1.3%, TFC -1.2%, SCHW -0.4%, MNS
moves among today's downgrades PENG -11.4%, FNB -2.6%, CRL -2.5%, BIRK -2.2%, FDUS -2.1%, HUBS -1.7%, ATAI -1.3%, TFC -1.2%, SCHW -0.4%, MNST +0.3%, ALGM +2.9%, SNEX +3.2% moves among today's negative initiations WDAY -1
EQUITY | Jul 20, 2026, 01:43 PM UTC
L
CRL downgraded from Outperform to Hold W/ $219 PT @ CLSA
CRL downgraded from Outperform to Hold W/ $219 PT @ CLSA
EQUITY | Jul 20, 2026, 12:20 PM UTC
L
CRL Downgrade from Outperform (2) to Hold (3) W/$219.00 PT at CLSA
CRL Downgrade from Outperform (2) to Hold (3) W/$219.00 PT at CLSA
EQUITY | Jul 20, 2026, 11:49 AM UTC
L
ACHV Cytisinicline's CRL was released by FDA, and no surprises with Q426 resubmission still planned; BUY, $13 PT @ Canaccord
ACHV Cytisinicline's CRL was released by FDA, and no surprises with Q426 resubmission still planned; BUY, $13 PT @ Canaccord
REGULATION | Jul 14, 2026, 12:17 PM UTC
H
Charles River price target raised to $260 from $220 at Morgan Stanley
Morgan Stanley raised the firm's price target on Charles River to $260 from $220 and keeps an Overweight rating on the shares. The firm is updating its model ahead of the earnings report.
EARNINGS | Jul 09, 2026, 10:57 AM UTC
L
Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Charles River Laboratories International, Inc. Insi
EQUITY | Jul 03, 2026, 04:25 PM UTC